CME Insider Filing: Sprague Reports Restricted Stock Vesting and Withholding
Rhea-AI Filing Summary
Suzanne Sprague, COO & Global Head of Clearing of CME Group Inc. (CME), reported stock transactions related to the vesting of restricted shares. On 09/15/2025 she surrendered 639 Class A shares to the company to satisfy tax withholding upon vesting and simultaneously acquired 3,044 Class A shares, leaving her with 11,172 Class A shares after those transactions. On 09/16/2025 she surrendered an additional 325 Class A shares for tax withholding, leaving 10,847 Class A shares reported as beneficially owned.
The Form 4 indicates these transactions were to meet tax obligations tied to restricted stock vesting; no cash purchases or open-market sales are reported and no derivative transactions are disclosed.
Positive
- Restricted stock vested, indicating compensation alignment between executive and company performance/goals
- Transactions were administrative (tax withholding) rather than open-market sales, suggesting no disposition intent
Negative
- None.
Insights
TL;DR Routine insider share surrenders to satisfy tax withholding after restricted stock vesting; no material change to reported ownership.
The filing documents standard compensation-related share withholding by a senior officer. Surrenders of 639 and 325 shares were executed to satisfy tax obligations tied to vesting events on 09/15/2025 and 09/16/2025. The transactions reduce the number of shares delivered to the insider but reflect compensation realization rather than active trading or intent to change ownership concentration. For governance review, this is a routine administrative transaction with limited investor implication.
TL;DR Transactions are administrative (tax withholding) around restricted stock vesting; reported beneficial ownership remains modest relative to issuer.
The Form 4 shows no open-market purchases or sales; the net beneficial holding reported after the transactions is 10,847 Class A shares. These actions reflect issuance/settlement mechanics of equity compensation and do not signal trading-based liquidity events or changes in insider conviction. Impact on float and share count is immaterial at the company level based on the disclosed amounts.
FAQ
What did Suzanne Sprague report on Form 4 for CME (CME)?
Were these open-market sales or purchases reported?
What is Suzanne Sprague's role at CME as shown on the filing?
Do the Form 4 entries show any derivative transactions?